First Tracks Biotherapeutics, Inc. 8-K

What Happened
First Tracks Biotherapeutics, Inc. announced its financial results for the three months ended March 31, 2026 by issuing a press release dated May 14, 2026. The company filed a Current Report on Form 8-K (Item 2.02) on May 14, 2026 to disclose the results; the press release is included as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 14, 2026 (Form 8-K).
• Reporting period: three months ended March 31, 2026.
• Disclosure type: Item 2.02 — Results of Operations and Financial Condition.
• Exhibit: 99.1 — press release announcing the quarter’s financial results.
• Report signed on behalf of the company by Ajim Tamboli, Chief Financial Officer.

Why It Matters
Quarterly results give investors an updated snapshot of the company’s recent financial performance (earnings, revenue, cash position and trends). The Form 8-K confirms the company has publicly released those results; shareholders and prospective investors should read the attached press release (Exhibit 99.1) for the specific numbers and any commentary on operations or outlook.